Journal of Orofacial Sciences

ORIGINAL ARTICLE
Year
: 2012  |  Volume : 4  |  Issue : 1  |  Page : 43--50

Topical application of green tea polyphenol (−) epigallocatechin-3-gallate for prevention of recurrent oral neoplastic lesions


Angela J Yoon1, Jing Shen2, Regina M Santella2, Elizabeth M Philipone1, Hui-Chen Wu2, Sidney B Eisig3, Andrew Blitzer4, Lanny G Close4, David J Zegarelli1 
1 Division of Oral and Maxillofacial Pathology, Columbia University Medical Center, New York, USA
2 Department of Environmental Health Sciences, Columbia University Medical Center, New York, USA
3 Division of Oral and Maxillofacial Surgery, Columbia University Medical Center, New York, USA
4 Department of Head and Neck Surgery, Columbia University Medical Center, New York, USA

Correspondence Address:
Angela J Yoon
630 West 168th Street, PH15W-1562, New York, NY 10032
USA

Objective: A preliminary study was conducted to investigate the feasibility of using an oral cancer chemopreventive agent (−)-epigallocatechin-3-gallate (EGCG), the most biologically active component in the green tea extract, in a form of DQswish-and-spitDQ mouthwash. Such application of EGCG is beneficial as it maximizes exposure of the oral mucosa to the agent but minimizes systemic side effect. Materials and Methods: The study was conducted on individuals suspected to have oral field cancerization who are at a high risk for developing recurrent oral precancerous and carcinomatous lesions. EGCG was used as a daily mouthwash for 7 days. EGCGSQs ability to modulate target molecules implicated in oral carcinogenesis was assessed by measuring the change in the expression levels of biomarkers. Results: Immunohistochemical expressions of phosphoactivated epidermal growth factor receptor (pEGFR), cyclooxygenase-2 (cox-2), and ki-67 were evaluated at baseline and at the endpoint (day 8). Although not statistically significant, overall decrease in expression levels of pEGFR (27.5%), cox-2 (15.9%), and ki-67 positive cells (51.8%) was observed following EGCG treatment. Moreover, a detectable level of EGCG was found in saliva but not in plasma after the 1-week treatment regime, demonstrating local availability of EGCG in oral mucosa without significant systemic absorption. Conclusion: To the best of our knowledge, this is the first study to explore use of oral cancer chemopreventive agent in the form of mouthwash in patients with oral field cancerization. Although a definitive conclusion was not reached due to limited sample size, if proven effective, EGCG therapy may offer a non-invasive preventive modality for oral field cancerization.


How to cite this article:
Yoon AJ, Shen J, Santella RM, Philipone EM, Wu HC, Eisig SB, Blitzer A, Close LG, Zegarelli DJ. Topical application of green tea polyphenol (−) epigallocatechin-3-gallate for prevention of recurrent oral neoplastic lesions.J Orofac Sci 2012;4:43-50


How to cite this URL:
Yoon AJ, Shen J, Santella RM, Philipone EM, Wu HC, Eisig SB, Blitzer A, Close LG, Zegarelli DJ. Topical application of green tea polyphenol (−) epigallocatechin-3-gallate for prevention of recurrent oral neoplastic lesions. J Orofac Sci [serial online] 2012 [cited 2021 Oct 22 ];4:43-50
Available from: https://www.jofs.in/article.asp?issn=0975-8844;year=2012;volume=4;issue=1;spage=43;epage=50;aulast=Yoon;type=0